CR20110321A - Anticuerpos contra la angiopoyetina 2 humana - Google Patents

Anticuerpos contra la angiopoyetina 2 humana

Info

Publication number
CR20110321A
CR20110321A CR20110321A CR20110321A CR20110321A CR 20110321 A CR20110321 A CR 20110321A CR 20110321 A CR20110321 A CR 20110321A CR 20110321 A CR20110321 A CR 20110321A CR 20110321 A CR20110321 A CR 20110321A
Authority
CR
Costa Rica
Prior art keywords
antibodies against
angiopoyetine
human
antibodies
ang
Prior art date
Application number
CR20110321A
Other languages
English (en)
Inventor
Ulrich Brinkmann
Remko Albert Griep
Klaus Kaluza
Anita Kavlie
Christian Klein
Joerg Thomas Regula
Werner Scheuer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40585738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110321(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20110321A publication Critical patent/CR20110321A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a anticuerpos contra la angiopoyetina 2 humana (anticuerpos anti-ANG-2), a métodos para su obtención, a composiciones farmacéuticas que contienen dichos anticuerpos y a usos de los mismos.
CR20110321A 2008-12-16 2011-06-09 Anticuerpos contra la angiopoyetina 2 humana CR20110321A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08021835 2008-12-16

Publications (1)

Publication Number Publication Date
CR20110321A true CR20110321A (es) 2011-07-14

Family

ID=40585738

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20110321A CR20110321A (es) 2008-12-16 2011-06-09 Anticuerpos contra la angiopoyetina 2 humana
CR20130418A CR20130418A (es) 2008-12-16 2013-08-28 Anticuerpos contra la angiopoyetina 2 humana (divisional exp. 2011-0321)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20130418A CR20130418A (es) 2008-12-16 2013-08-28 Anticuerpos contra la angiopoyetina 2 humana (divisional exp. 2011-0321)

Country Status (33)

Country Link
US (12) US8133979B2 (es)
EP (1) EP2379592B1 (es)
JP (2) JP5559191B2 (es)
KR (2) KR101381012B1 (es)
CN (3) CN103739709B (es)
AR (2) AR074756A1 (es)
AU (1) AU2009328613B2 (es)
BR (2) BR122013022089B1 (es)
CA (2) CA2744624C (es)
CL (2) CL2011001285A1 (es)
CR (2) CR20110321A (es)
CY (1) CY1116264T1 (es)
DK (1) DK2379592T3 (es)
EC (2) ECSP11011139A (es)
ES (1) ES2534635T3 (es)
HR (1) HRP20150439T1 (es)
HU (1) HUE024545T2 (es)
IL (2) IL213039A (es)
MA (1) MA32876B1 (es)
MX (1) MX2011005908A (es)
MY (2) MY155654A (es)
NZ (2) NZ600005A (es)
PE (2) PE20120551A1 (es)
PH (1) PH12013502192A1 (es)
PL (1) PL2379592T3 (es)
PT (1) PT2379592E (es)
RU (2) RU2569461C2 (es)
SG (1) SG172216A1 (es)
SI (1) SI2379592T1 (es)
TW (2) TWI482631B (es)
UA (2) UA105151C2 (es)
WO (1) WO2010069532A1 (es)
ZA (2) ZA201103990B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
EA021967B1 (ru) 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
CN102712696A (zh) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
TW201138821A (en) * 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102221615A (zh) * 2011-03-31 2011-10-19 广州华灿医药科技有限公司 一种基于Angiogenin检测的双抗夹心ELISA方法
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US9512220B2 (en) 2011-04-05 2016-12-06 Neopharm Co., Ltd. Antibodies against angiopoietins 1 and 2, and their use
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
DK2760471T3 (en) 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
MX2014014162A (es) * 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
ES2597228T3 (es) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
KR101967345B1 (ko) 2012-10-18 2019-04-09 삼성전자주식회사 안지오포이에틴-2와 인테그린 간의 결합을 저해하는 펩타이드 및 그 용도
WO2014108854A1 (en) * 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
JP6469644B2 (ja) 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
KR102131371B1 (ko) 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 특이적 항체 및 그의 용도
US9902767B2 (en) 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
CN105611944A (zh) * 2013-12-20 2016-05-25 豪夫迈·罗氏有限公司 抗ang2抗体和cd40激动剂的组合疗法
KR102206029B1 (ko) 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
EP3116903A2 (en) 2014-03-14 2017-01-18 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
US9957333B2 (en) * 2014-04-17 2018-05-01 Case Western Reserve University Anti-CEP antibody or fragment thereof
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
US9994632B2 (en) 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
EP3207059A1 (en) 2014-10-17 2017-08-23 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
WO2016075035A1 (en) * 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
SG11201705278QA (en) 2015-01-28 2017-07-28 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
EP3334762A1 (en) 2015-08-14 2018-06-20 Allergan, Inc. Heavy chain only antibodies to pdgf
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
US10703810B2 (en) 2015-11-30 2020-07-07 Pieris Australia Pty Ltd. Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
KR102143132B1 (ko) * 2016-12-26 2020-08-10 기초과학연구원 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
EP3600442A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
KR102497171B1 (ko) * 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
CN119033684A (zh) 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 抗体制剂
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CA3169967A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
CA3190173A1 (en) * 2020-06-22 2021-12-30 Innovent Biologics (Suzhou) Co., Ltd. Anti-ang-2 antibody and use thereof
CN116472285A (zh) * 2020-08-07 2023-07-21 南京金斯瑞生物科技有限公司 针对人血管生成素-2的抗体及其用途
TW202228789A (zh) 2020-10-15 2022-08-01 美商建南德克公司 用於長效遞送治療劑之多能蛋白聚醣（ｖｇ１）的玻尿酸結合衍生物
CA3217029A1 (en) 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
EP4590328A2 (en) * 2022-09-19 2025-07-30 Sonoma Biotherapeutics, Inc. Citrullinated antigen-specific chimeric antigen receptors for targeting regulatory t cells to treat hidradenitis suppurativa
CN117362392B (zh) * 2023-09-28 2026-06-12 中国科学院近代物理研究所 一种靶向angpt2的多肽及用于诊断脑胶质瘤的放射性分子探针
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
RU2277411C1 (ru) * 2004-12-15 2006-06-10 Ольга Алексеевна Кост Фармацевтическая композиция для лечения глазных болезней, связанных с нарушением микроциркуляции и/или воспалительными процессами
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
CA2799802A1 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP2377554A1 (en) * 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
EP1962903B1 (en) 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
NZ569988A (en) * 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
US8507656B2 (en) * 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
SI3495387T1 (sl) * 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil

Also Published As

Publication number Publication date
IL226350A (en) 2016-10-31
ECSP11011139A (es) 2011-07-29
US20140065151A1 (en) 2014-03-06
MA32876B1 (fr) 2011-12-01
IL226350A0 (en) 2013-06-27
RU2013140625A (ru) 2015-03-10
CY1116264T1 (el) 2017-02-08
US20210388071A1 (en) 2021-12-16
PE20140814A1 (es) 2014-07-10
US20120141500A1 (en) 2012-06-07
TWI396549B (zh) 2013-05-21
SI2379592T1 (sl) 2015-06-30
KR101381012B1 (ko) 2014-04-11
CN102746400A (zh) 2012-10-24
CN103739709B (zh) 2016-08-24
JP2014000089A (ja) 2014-01-09
EP2379592B1 (en) 2015-02-11
US9340609B2 (en) 2016-05-17
US20180282404A1 (en) 2018-10-04
BR122013022089B1 (pt) 2021-10-13
TW201322996A (zh) 2013-06-16
CN102257008A (zh) 2011-11-23
RU2569461C2 (ru) 2015-11-27
CR20130418A (es) 2013-10-04
US8361747B2 (en) 2013-01-29
US20200262904A1 (en) 2020-08-20
HK1172349A1 (zh) 2013-04-19
UA105151C2 (uk) 2014-04-10
CA2744624C (en) 2018-01-02
TWI482631B (zh) 2015-05-01
ZA201103990B (en) 2016-01-27
US20120142091A1 (en) 2012-06-07
IL213039A (en) 2015-03-31
CA2744624A1 (en) 2010-06-24
KR101445518B1 (ko) 2014-10-01
RU2569107C2 (ru) 2015-11-20
KR20130103822A (ko) 2013-09-24
US20140065707A1 (en) 2014-03-06
US9073986B2 (en) 2015-07-07
TW201026328A (en) 2010-07-16
SG172216A1 (en) 2011-07-28
PT2379592E (pt) 2015-03-24
PL2379592T3 (pl) 2015-07-31
NZ600005A (en) 2012-08-31
HUE024545T2 (hu) 2016-01-28
ECSP13011139A (es) 2014-10-31
US20150284457A1 (en) 2015-10-08
MX2011005908A (es) 2011-06-20
CN103739709A (zh) 2014-04-23
US20130156789A1 (en) 2013-06-20
US20170029493A1 (en) 2017-02-02
CL2011001285A1 (es) 2011-09-16
ZA201307297B (en) 2019-07-31
WO2010069532A8 (en) 2012-05-10
AU2009328613B2 (en) 2013-09-05
NZ592856A (en) 2012-06-29
US9109027B2 (en) 2015-08-18
BR122013022089A2 (pt) 2019-05-28
PH12013502192B1 (en) 2015-10-12
US8133979B2 (en) 2012-03-13
MY155654A (en) 2015-11-13
HRP20150439T1 (hr) 2015-05-22
UA103912C2 (uk) 2013-12-10
PH12013502192A1 (en) 2015-10-12
RU2011129204A (ru) 2013-01-27
AR074756A1 (es) 2011-02-09
CN102746400B (zh) 2015-12-16
AU2009328613A1 (en) 2010-06-24
JP5559191B2 (ja) 2014-07-23
WO2010069532A1 (en) 2010-06-24
BRPI0923434A2 (pt) 2017-09-19
KR20110084536A (ko) 2011-07-25
PE20120551A1 (es) 2012-05-21
IL213039A0 (en) 2011-07-31
ES2534635T3 (es) 2015-04-27
JP2012511897A (ja) 2012-05-31
MY158438A (en) 2016-10-14
EP2379592A1 (en) 2011-10-26
DK2379592T3 (en) 2015-03-02
CA2916481C (en) 2018-05-15
HK1195775A1 (zh) 2014-11-21
CA2916481A1 (en) 2010-06-24
AR092487A2 (es) 2015-04-22
JP5814317B2 (ja) 2015-11-17
US20100159587A1 (en) 2010-06-24
US20230227543A1 (en) 2023-07-20
US8399626B2 (en) 2013-03-19
CL2012003054A1 (es) 2012-12-14

Similar Documents

Publication Publication Date Title
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
CR20110166A (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2
ECSP10010295A (es) Formulacion de anticuerpo
ECSP12011701A (es) Anticuerpos anti-cdcp1 humanizados
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
ECSP12011995A (es) Anticuerpos anti-her3 y usos de los mismos
CR11731A (es) Composiciones y procedimientos para su preparación y uso
CR20140431A (es) Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
ECSP088632A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
ECSP11010822A (es) 4-fenil-1h-pirazoles insecticidas
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
MX374468B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
UY33208A (es) Composiciones que comprenden productos de azúcar cisteína
BRPI0800596A2 (pt) método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
GT201200066A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6390001A2 (es) Anticuerpos contra la angiopoyetina 2 humana
GT200800254A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparacion, composiciones que las contienen y utilizacion.